Article

Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma

2021-01-06

Abstract excerpt

<h4>Background</h4> We conducted a meta-analysis of previous adenoviral p53 (Ad-p53) treatment data in recurrent head and neck squamous cell carcinoma (HNSCC) patients to identify optimal Ad-p53 treatment methods for future clinical trials. <h4>Methods</h4> The meta-analysis involved recurrent HNSCC patients treated with Ad-p53 for whom p53 genotyping and immunohistochemistry tumor biomarker studies had been perfo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d588d336-3c3e-578f-af95-47e0ab228fec
DOI: 10.1101/2021.01.06.20248743

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell CarcinomaDOI 10.1101/2021.01.06.20248743Read

Head and neck cancer: Response to p53‐based therapeuticsSemantic proximity Read

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based AnalysisSemantic proximity Read

p53-based therapeutics for head and neck squamous cell carcinoma.Semantic proximity Read

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read

Tumor Suppressor Immune Gene Therapy to Reverse Immunotherapy ResistanceSemantic proximity Read

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.Semantic proximity Read

Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.Semantic proximity Read

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Semantic proximity Read

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read

Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.Semantic proximity Read